Calloway Labs Revenue and Competitors
Estimated Revenue & Valuation
- Calloway Labs's estimated annual revenue is currently $10.5M per year.
- Calloway Labs's estimated revenue per employee is $155,000
Employee Data
- Calloway Labs has 68 Employees.
- Calloway Labs grew their employee count by -3% last year.
Calloway Labs's People
Name | Title | Email/Phone |
---|
Calloway Labs Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Calloway Labs?
Calloway is one of the nation´s fastest growing clinical toxicology laboratories. We specialize in proprietary testing protocols that address critical challenges facing today´s drug treatment and medical professionals. This includes Substance Abuse Screening and Drug Therapy Compliance. Calloway is always at the forefront of technology embracing the latest techniques for the entire testing lifecycle including Insta-Cups, high volume screening, in-house GC/MS and MRO review. We were one of the first clinical labs to provide test results via the internet, integrate a seamless Medical Review Officer (MRO) process, and quantify results for buprenorphine and oxycodone. We work with industry leaders to educate medical and treatment professional in the latest developments in patient care and regulatory compliance.
keywords:N/AN/A
Total Funding
68
Number of Employees
$10.5M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.9M | 68 | 10% | N/A |
#2 | $18M | 69 | 8% | N/A |
#3 | $20.5M | 69 | 0% | N/A |
#4 | $12.9M | 70 | 19% | N/A |
#5 | $7.5M | 70 | -3% | N/A |